A blood-based biomarker assay for multiple sclerosis (MS) disease activity provides actionable insights that supplement standard MS evaluations, especially for treatment initiation and de-escalation ...

A research team at the Medical University of Vienna has developed a blood test that allows the identification of individuals at risk for developing multiple sclerosis (MS) with a high degree of ...

LONDON — Previous research has shown that providing a clinically definite multiple sclerosis (MS) diagnosis often takes several weeks or even months. But new research suggests that a new "technology ...

Real-world data show increasing clinical use of blood-based biomarker panels to monitor disease activity and treatment response in multiple sclerosis.

Scientists have found blood protein signals that may flag multiple sclerosis up to seven years before symptoms begin. Spotting early warning signs means more opportunities to treat or prevent multiple ...

Publication in the journal ‘Brain’ confirms complementary roles of the biomarkers for predicting relapse and chronic disability progression in multiple sclerosis (MS) Simoa technology paired with an ...

Octave Bioscience Forms Strategic Collaboration with Quest Diagnostics to Expand Patient Access to the Octave® Multiple Sclerosis Disease Activity (MSDA) Test Across the United States Collaboration ...

For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...